美国Vertex  
Vertex公司是一家专注于研究口服小分子药剂新的开发方法、使用基于结构的合理药剂进行设计的先驱性的医药品研究开发企业，主要设计开发防止HIV感染、AIDS自免疫系统缺失、癌症、血红蛋白障碍、炎症等新药。近年来这家公司的一些新药频受关注，比如今年，其囊性纤维化治疗药物VX- 770的临床三期研究被分析师认为取得了历史性的突破：这种药物起效明显，在一秒钟内就能引发肺功能改善——即FEV1用力呼气量——在48周与安慰剂的对比试验中，所有关键的次要终点在参与VX- 770试验组的成员都得到改进。除此之外，其最新的治疗丙型肝炎的药物(telaprevir)也通过FDA的审批。

Vertex creates new possibilities in medicine. Our team discovers, develops and commercializes innovative therapies so people with serious diseases can lead better lives.

Vertex scientists and our collaborators are working on new medicines to advance the treatment of hepatitis C, cystic fibrosis, epilepsy and other life-threatening diseases.

Vertex isn’t a conventional pharmaceutical company. Each and every person at Vertex is driven by a passion for fearless innovation and a bold desire to transform the lives of millions with new medicines. Vertex has ongoing worldwide research programs and sites in the U.S., U.K. and Canada and employs over 1800 people.